Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TKT Brings Back Astrue; Legal, Political Focus Suggests New Biotech Model

Executive Summary

Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions

You may also be interested in...



TKT Replagal Decision On New Trial Expected In Four Months

Transkaryotic Therapies will decide this summer after meeting with FDA whether to conduct additional clinical trials with its Fabry disease agent Replagal

TKT Replagal Decision On New Trial Expected In Four Months

Transkaryotic Therapies will decide this summer after meeting with FDA whether to conduct additional clinical trials with its Fabry disease agent Replagal

Fabrazyme Market Could Grow With Dialysis Patients, Women, Children

Genzyme expects the Fabry disease incidence in dialysis patients to nearly double the market for its Fabry therapy Fabrazyme

Related Content

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel